呼吸道合胞病毒感染防治研究

一伟 苗(重庆医科大学附属儿童医院呼吸中心，中国·重庆 400014)

摘要

呼吸道合胞病毒（RSV)是引起婴幼儿毛细支气管炎、肺炎的重要病原。RSV感染引起的毛细支气 管炎诊断并不困难，但关于感染后喘息、发生哮喘的机制并不明确。目前尚没有防治RSV感染的疫苗与特效药。随着对RSV感染预防控制及治疗方法的深入研宄，为临床面对RSV挑战提供了新思路与前景。

关键词

呼吸道合胞病毒；毛细支气管炎；药物疗效；婴幼儿

参考

Anderson LJ,Heilman CA. Protective and disease enhancing immune responses to respirotory syncytial virus [J]. J Infect Dis, 1995(1):1-7.

Openshaw PJM. Immunity and irranunopathology to respiratory syncytial virus. The mouse model[J]. Am J Respir Crit Care Med, 1995; 152:pps63-66.

Roman M, Calhoun WJ, Hinton DI, et al . Respiratory syncytial virus infection in infant is associated with predcxninant Th-2 like response [J]. Am J Respir Crit Care Med, 1997; 156: ppl90-195.

Paludan SR. Interleukin-4 and interferon-y: the quintessence of a mutual antagonistic relationship [J]. Scand J Immunol 1998; 48:459-468.

Taylor G,Stott EJ,Furse J, et al . Protective epitopes on the fution of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies[J].J Gen Virol,1992;73:2217-2223.

Alwan WH,Record FM,Openshaw PJM. Phenotype and function al characterization of T cellines specific for individual respiratory syncytial virus proteins[J]. J Immunology 1993; 150: 5211-5218.

耿学辉,朱汝男,孙晓鸥,等.我国部分地区呼吸道合胞病毒分离株的亚型鉴定[J].中华儿科杂志,1997(7):405~407

Hendry RM, Bums JC, Walsh Eet,etal . Strain〜specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus[J]. J Infect Dis,1998 (157) :640-647.

Johnson PR, Olmsted RA, Prince GA, et al . Antigenic relationness between glycoproteins of human respiratory syncytial virus sulroups A and B: evaluation of the contribution of F and G glycoproteins to immuity[J].J Virol, 1987(61):3163-3166.

陈慧中,苏英姿,齐春华,等.A亚型呼吸道合胞病毒毛细支气管炎的临床研究[J].中华儿科杂志,1999 (1):32-34.

孔晓慧,刘春艳,寿好长,等.呼吸道合胞病毒感染程度与危险因 素的相关分析[J].中华儿科杂志,2000 (10) :603-606.

姚龙整理.常见病毒性急性呼吸道感染的防治[J].中华儿科杂志,2000(10):641 -645.

齐春华,陈慧中,王之梁,等.基因重组干扰素7治疗呼吸道合胞病毒所致毛细支气管炎的临床疔效分析[J].中华儿科杂志,2000(10):599-602.

Graham BS. Pathogenesis of respiratory syncytial virus vaccineaugu- mented pathology [J]. Am J Respir Crit Care Med, 1995(152):63-66.

Tang TW, Graham BS. Inerleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine im- munogenicity[J]. J Inefect Dis, 1995( 172): 734-738.

Tang YW,Graham BS. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotxic T lymphocyte activity in mice challenged with respiratory syncytial virus[J]. J Clin Invest 1994(94):1953-1958.

Neuzil KM, Johnson JE,Tang YW, et al.Adjuvants influence the quantitative and quanlitative immune response in BALB/C mice immunized with respiratory syncytial virus PG subunit vaccine[J]. Vaccine 1997(5):525-532.

Cramer H. Antisense approaches for inhibiting respiratory syncytial virus [J]. Expert Opin Biol Ther, 2005 (2):207-220.

Hall CB, Walsh EE, Schnabel KC, et at. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children [J]. J Infect Dis, 1990 (6):1283-1290.

Broughton S, Bhat R, Roberts A,et al. Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants [J]. Arch Dis Child,2006(1):26-30.

Wainwright C,Altamirano L,Cheney M,et al. A multicenter,randomized,double-blind,controlled trial of nebulized epinephrine in infants with acute bronchiolitis [J]. N Engl J Med, 2003(1): 27-35.

DOI: http://dx.doi.org/10.26549/ptvd.v1i1.5429